4888 — Stella Pharma Share Price
0.000.00%
Last trade - 00:00- ¥11bn
- ¥8bn
- ¥269m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.66 | ||
| Price to Tang. Book | 3.73 | ||
| Price to Free Cashflow | 117.67 | ||
| Price to Sales | 33.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.81% | ||
| Return on Equity | -23.66% | ||
| Operating Margin | -206.67% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | 205.97 | 100.1 | 229.07 | 269.49 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 1st, 2007
- Public Since
- April 22nd, 2021
- No. of Shareholders
- 8,861
- No. of Employees
- 44
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 34,031,993
- Address
- 3-2-7, Koraibashi, Chuo-ku, OSAKA-SHI, 541-0043
- Web
- https://stella-pharma.co.jp/
- Phone
- +81 647071516
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4888
Similar to 4888
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Stella Pharma share price?
As of Today at 23:26 UTC, shares in Stella Pharma are trading at ¥320. This share price information is delayed by 15 minutes.
How has the Stella Pharma share price performed this year?
Shares in Stella Pharma last closed at ¥320 and the price had moved by +20.75% over the past 365 days. In terms of relative price strength the Stella Pharma share price has outperformed the Nikkei 225 Index by +31.88% over the past year.
What are the analyst and broker recommendations for Stella Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Stella Pharma dividend yield?
Stella Pharma does not currently pay a dividend.
Does Stella Pharma pay a dividend?
Stella Pharma does not currently pay a dividend.
When does Stella Pharma next pay dividends?
Stella Pharma does not currently pay a dividend.
How do I buy Stella Pharma shares?
To buy shares in Stella Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Stella Pharma?
As of the previous close price of ¥320, shares in Stella Pharma had a market capitalisation of ¥11bn.
Where are Stella Pharma shares listed?
Here are the trading details for Stella Pharma:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4888
What kind of share is Stella Pharma?
Based on an overall assessment of its quality, value and momentum Stella Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Stella Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Stella Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stella Pharma. Over the past six months, its share price has underperformed the Nikkei 225 Index by -26.2%.
As of the last closing price of ¥320, shares in Stella Pharma were trading -31.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Stella Pharma PE Ratio?
The Stella Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥320.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Stella Pharma?
We do not have data on Stella Pharma's directors